MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
P/E ratio for MediciNova, Inc. (MNOV)
P/E ratio as of 2023: -8.58
According to MediciNova, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.58. At the end of 2022 the company had a P/E ratio of -7.15.
P/E ratio history for MediciNova, Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -8.58 |
| 2022 | -7.15 |
| 2021 | -12.85 |
| 2020 | -16.86 |
| 2019 | -22.48 |
| 2018 | -22.90 |
| 2017 | -20.36 |
| 2016 | -18.31 |
| 2015 | -10.67 |
| 2014 | -7.96 |
| 2013 | -10.99 |
| 2012 | -2.58 |
| 2011 | -1.42 |
| 2010 | -2.90 |
| 2009 | -4.18 |
| 2008 | -0.88 |
| 2007 | -1.11 |
| 2006 | -3.77 |
| 2005 | -3.81 |
| 2004 | -0.01 |
| 2003 | -0.09 |
| 2002 | -0.08 |
| 2001 | -0.31 |